Akouos (AKUS) Stock Price, News & Analysis

Company Overview

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $13.29 to $13.29
• 50-Day Range: $13.29 to $13.29
• 52-Week Range: $2.32 to $13.60
• Volume: 440 shs
• Average Volume: 344,411 shs
• Market Capitalization: $490.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKUS Stock Analysis - Frequently Asked Questions

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.04.

When did Akouos IPO?

Akouos (AKUS) raised $124 million in an IPO on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akouos investors own include Advanced Micro Devices (AMD), Atreca (BCEL), Editas Medicine (EDIT), Homology Medicines (FIXX), Avidity Biosciences (RNA), Alector (ALEC) and Gossamer Bio (GOSS).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AKUS
• CIK: 1722271
• Web: www.akouos.com
• Phone: 857-410-1818
• Fax: N/A
• Employees: 103
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-86,670,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -45.09%
• Return on Assets: -36.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.30
• Quick Ratio: 17.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.90 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 36,936,000
• Free Float: 35,163,000
• Market Cap: $490.88 million
• Optionable: Not Optionable
• Beta: -0.55